FDA approves new Alzheimer's drug, offering hope for slower cognitive decline

The U.S. Food and Drug Administration gave a green light to Eli Lilly's donanemab for patients with early Alzheimer's, making it the second approved drug for slowing the progress of the brain-wasting disease.A new Alzheimer's drug, donanemab, is giving new hope to those living with the condition, but it doesn't come without side effects and it's not a cure. Dr. Roger Wong, a clinical professor of geriatric medicine goes over why it's a big deal and what are the risks.U.S.

This view shows tests for patients with Alzheimer's disease at a memory clinic. Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out simple tasks. "It's been difficult as a dementia specialist — I diagnose my patients with Alzheimer's and then every year I see them get worse and they progress until they die."Both Kisunla and the Japanese drug, Leqembi, are laboratory-made antibodies, administered by IV, that target one contributor to Alzheimer's — sticky amyloid plaque buildup in the brain. Questions remain about which patients should get the drugs and how long they might benefit.

Kisunla and Leqembi are not listed in Health Canada's database of medications approved for use in this country. "Certainly getting an infusion once a month is more appealing than getting it every two weeks," Schindler said.In the company's study, patients were taken off Kisunla once their brain plaque reached low levels. More than 40 per cent of patients stopped taking the drug after one year. Discontinuing the drug could reduce the costs and safety risks of long-term use. It's not yet clear when patients might need to resume infusions.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Lilly Wins FDA Approval for New Drug to Slow Alzheimer’s DiseaseEli Lilly & Co.’s Alzheimer’s treatment was cleared in the US as the second drug to slow progression of the mind-robbing disease that afflicts 6 million Americans.
Source: BNNBloomberg - 🏆 83. / 50 Read more »

FDA approves a second Alzheimer's drug that can modestly slow diseaseWASHINGTON (AP) —
Source: YahooFinanceCA - 🏆 47. / 63 Read more »

U.S. FDA approves second Alzheimer’s drug that can modestly slow diseaseThe drug could provide a new option for patients in the early stages of the incurable, memory-destroying ailment
Source: globeandmail - 🏆 5. / 92 Read more »

FDA approves a second Alzheimer's drug that can modestly slow diseaseU.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.
Source: CTVNews - 🏆 1. / 99 Read more »

FDA approves Eli Lilly's Alzheimer's drug KisunlaEli Lilly's (LLY) Alzheimer's treatment drug Kisunla has gained approval by the US Food and Drug Administration. Yahoo Finance Health Reporter Anjalee...
Source: YahooFinanceCA - 🏆 47. / 63 Read more »

Lilly Alzheimer’s Drug Seen Effective by FDA Advisory PanelEli Lilly & Co.’s treatment for Alzheimer’s disease works in at least some patients, according to a US advisory panel.
Source: BNNBloomberg - 🏆 83. / 50 Read more »